These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 29523912)

  • 61. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
    Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R
    Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Disease stability over five years in people with multiple sclerosis treated with cladribine tablets: a plain language summary.
    Giovannoni G; Comi G; Rammohan K; Rieckmann P; Dangond F; Jack D; Vermersch P
    Neurodegener Dis Manag; 2022 Dec; 12(6):295-301. PubMed ID: 36017780
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Real-world evidence for cladribine tablets in multiple sclerosis: further insights into efficacy and safety.
    Moser T; Ziemssen T; Sellner J
    Wien Med Wochenschr; 2022 Nov; 172(15-16):365-372. PubMed ID: 35451662
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunological consequences of cladribine treatment in multiple sclerosis: A real-world study.
    Rolfes L; Pfeuffer S; Huntemann N; Schmidt M; Su C; Skuljec J; Aslan D; Hackert J; Kleinschnitz K; Hagenacker T; Pawlitzki M; Ruck T; Kleinschnitz C; Meuth SG; Pul R
    Mult Scler Relat Disord; 2022 Aug; 64():103931. PubMed ID: 35690010
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Potential mechanisms of action related to the efficacy and safety of cladribine.
    Baker D; Pryce G; Herrod SS; Schmierer K
    Mult Scler Relat Disord; 2019 May; 30():176-186. PubMed ID: 30785074
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study.
    Giovannoni G; Singer BA; Issard D; Jack D; Vermersch P
    Mult Scler; 2022 Jul; 28(8):1219-1228. PubMed ID: 34634968
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
    Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist TP; Coyle PK; Dangond F; Alexandri N; Galazka A
    Neurodegener Dis Manag; 2022 Dec; 12(6):303-310. PubMed ID: 36017797
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prospective observational study to evaluate treatment satisfaction and effectiveness in patients with relapsing multiple sclerosis starting cladribine tablets (CLADREAL) in Italy.
    Filippi M; Ferrè L; Zanetta C; Rizzi C; Pessina G; Assogna F; Rocca MA
    Front Neurol; 2024; 15():1379712. PubMed ID: 38638312
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Remission of early persistent cladribine-induced neutropenia after filgrastim therapy in a patient with Relapsing - Remitting Multiple Sclerosis.
    Maniscalco GT; Annunziata M; Ranieri A; Alfieri G; Renna R; Iorio WD; Guarcello G; Cerillo I; Improta G; Florio C
    Mult Scler Relat Disord; 2020 Aug; 43():102151. PubMed ID: 32417665
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical and biological predictors of Cladribine effectiveness in Multiple Sclerosis: A real-world, single Centre study considering a two-year interval from year-2 dosing.
    Manni A; Oggiano F; Palazzo C; Panetta V; Gargano CD; Mangialardi V; Guerra T; Iaffaldano A; Caputo F; Iaffaldano P; Ruggieri M; Trojano M; Paolicelli D
    J Neurol Sci; 2024 Jul; 462():123070. PubMed ID: 38850773
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS.
    de Stefano N; Barkhof F; Montalban X; Achiron A; Derfuss T; Chan A; Hodgkinson S; Prat A; Leocani L; Schmierer K; Sellebjerg F; Vermersch P; Wiendl H; Keller B; Roy S;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35701185
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
    Mao Z; Álvarez-González C; Allen-Philbey K; De Trane S; Yildiz O; Campion T; Adams A; Turner BP; Marta M; Gnanapavan S; Espasandin M; Mathews J; Giovannoni G; Baker D; Schmierer K
    Mult Scler Relat Disord; 2019 Jan; 27():247-253. PubMed ID: 30419510
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.
    Giovannoni G; Boyko A; Correale J; Edan G; Freedman MS; Montalban X; Rammohan K; Stefoski D; Yamout B; Leist T; Aydemir A; Borsi L; Verdun di Cantogno E
    Mult Scler; 2023 May; 29(6):719-730. PubMed ID: 37012898
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
    Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
    Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
    Murphy JA; Harris JA; Crannage AJ
    Neuropsychiatr Dis Treat; 2010 Oct; 6():619-25. PubMed ID: 20957121
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cladribine Tablets for Relapsing-Remitting Multiple Sclerosis: A Clinician's Review.
    Giovannoni G; Mathews J
    Neurol Ther; 2022 Jun; 11(2):571-595. PubMed ID: 35318617
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cladribine effects on patient-reported outcomes and their clinical and biometric correlates in highly active relapsing multiple sclerosis at first switch: the observational, multicenter, prospective, phase IV CLADFIT-MS study.
    Borriello G; Chisari CG; Maimone D; Mirabella M; Paolicelli D; Assogna F; Caradonna S; Patti F
    Front Neurol; 2024; 15():1422078. PubMed ID: 39114529
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study.
    Rammohan K; Giovannoni G; Comi G; Cook S; Rieckmann P; Soelberg Sørensen P; Vermersch P; Hamlett A; Kurukulasuriya N;
    Mult Scler Relat Disord; 2012 Jan; 1(1):49-54. PubMed ID: 25876451
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study.
    Brochet B; Solari A; Lechner-Scott J; Piehl F; Langdon D; Hupperts R; Selmaj K; Patti F; Brieva L; Maida EM; Alexandri N; Smyk A; Nolting A; Keller B; Montalban X; Kubala Havrdova E
    Mult Scler; 2023 Dec; 29(14):1808-1818. PubMed ID: 37978852
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The Development of the Combination Drug Leukovir
    Kalinichenko EN; Babitskaya SV
    Curr Drug Targets; 2023; 24(16):1271-1281. PubMed ID: 38037996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.